PIPELINE
NIT is currently conducting multiple clinical trials of NT-I7 as a monotherapy and in combination with leading immunotherapeutics such as checkpoint inhibitors and more.
In addition, NIT is relentlessly conducting proof-of-concept animal studies in additional indications to further strengthen our pipeline and broaden the proof of applicability of NT-I7.
NeoImmuneTech provides this link as a courtesy and does not control the content of the site you are about to enter.
Do you wish to continue?